The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.40
Bid: 29.20
Ask: 29.90
Change: -0.35 (-1.18%)
Spread: 0.70 (2.397%)
Open: 29.50
High: 30.00
Low: 29.40
Prev. Close: 29.75
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

27 Jul 2010 07:00

RNS Number : 9569P
EKF Diagnostics Holdings PLC
27 July 2010
 



EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Directorate Change

 

EKF Diagnostics Holdings plc (AIM: EKF), which has recently refocused on the in-vitro diagnostic devices market, announces that David Evans (formerly Non-Executive Chairman) has today been appointed Executive Chairman of the Company.

 

Mr. Evans was appointed to the Board on 26th November 2009 when the Company announced a change in strategy to focus on building a business within the diagnostics market place through acquisition and organic growth. Since his appointment the Company has successfully acquired EKF-diagnostic GmbH, through a reverse takeover and has continued to divest itself from the sports apparel industry. With David's wealth of experience and success within the diagnostic and healthcare industry and in particular at this stage of the Company's development the Board of directors decided that it would be in shareholders best interests to appoint David to the position of Executive Chairman. 

 

In addition the Board announces that David's remuneration will be at the same level as previously agreed for his non-executive role at £40,000 per annum and he would like to receive this in new equity to be issued every six months, based upon the average share price during this period.

 

Julian Baines, EKF's CEO, commented: "I am delighted David has accepted this role as I have worked with him for a number years and hugely value his support and wealth of knowledge within the industry. David's contribution working alongside me as an executive will be invaluable at this stage of the Company's pro-active buy and build strategy."

 

 

Enquiries:

 

EKF Diagnostics Holdings plc

Julian Baines, CEO

 

Tel: 020 7823 1733

Mob: 07788 420 859

Zeus Capital - Nominated Adviser and Joint Broker

Ross Andrews

Tom Rowley

 

Tel: 0161 831 1512

Matrix Corporate Capital LLP - Joint Broker

Tel: 020 3206 7000

Rob Naylor

 

 

Walbrook PR

Paul McManus

 

Tel: 020 7933 8780

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGUMAMUPUGMQ
Date   Source Headline
7th Apr 20207:00 amRNSFinal Results
24th Mar 20207:00 amRNSDetailed trading review including COVID-19 update
20th Mar 20207:00 amRNSInvestor results briefing update
4th Mar 20207:00 amRNSNotice of Results
24th Feb 20201:56 pmRNSHolding(s) in Company
29th Jan 20207:00 amRNSTrading update
6th Nov 201912:14 pmRNSTrading update and performance bonuses
10th Sep 20197:00 amRNSHalf-year Report
10th Sep 20197:00 amRNSPreferred Partner Arrangement with Mount Sinai
21st Aug 20197:00 amRNSNotice of Results
8th Aug 20194:40 pmRNSSecond Price Monitoring Extn
8th Aug 20194:35 pmRNSPrice Monitoring Extension
15th Jul 20197:00 amRNSTrading update
11th Jun 20192:15 pmRNSCancellation of share options
7th Jun 20194:30 pmRNSHolding(s) in Company
28th May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 201911:21 amRNSResult of AGM
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
25th Apr 20197:00 amRNSPosting of AR & Accounts and Notice of AGM
13th Mar 20197:00 amRNSFinal Results
8th Mar 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUS FDA approval for Quo-Test analyser
22nd Jan 20197:00 amRNSUpdate on McKesson US distribution agreement
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
16th Jan 20197:00 amRNSTrading update
20th Dec 20187:00 amRNSUpdate regarding planned change of NOMAD
19th Dec 20184:56 pmRNSPDMR dealing
7th Dec 20183:15 pmRNSPurchase of own shares and PDMR Dealing
30th Nov 20182:35 pmRNSTotal Voting Rights
22nd Nov 20185:13 pmRNSPurchase of own shares and PDMR Dealing
21st Nov 20182:08 pmRNSPurchase of own shares and PDMR Dealing
20th Nov 20185:18 pmRNSPurchase of own shares and PDMR Dealing
14th Nov 20182:20 pmRNSShare Buy-Back
9th Nov 20181:48 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings
2nd Nov 20188:00 amRNSSchedule 1 update - Renalytix AI plc
1st Nov 20185:30 pmRNSUpdate regarding AIM admission of RenalytixAI
31st Oct 20186:00 pmRNSResult of RO by RenalytixAI & Fundraising Update
23rd Oct 20182:00 pmRNSSchedule One Update - Renalytix AI plc
23rd Oct 201811:01 amRNSUpdate to distribution timetable
22nd Oct 20185:23 pmRNSApproval of distribution of shares in RenalytixAI
19th Oct 201812:10 pmRNSResult of General Meeting
19th Oct 201811:00 amRNSSchedule One - Renalytix AI plc
12th Oct 20187:00 amRNSInvestor presentation
11th Oct 20186:03 pmRNSLaunch of Restricted Offer by Renalytix AI plc
11th Oct 20185:21 pmRNSFundraising and AIM admission of Renalytix AI plc
11th Oct 20184:01 pmRNSFundraising and AIM admission of Renalytix AI plc
27th Sep 201810:15 amRNSNotice of GM
19th Sep 20187:00 amRNSHalf-year Report
17th Sep 201812:21 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.